Kotra Pharma (M) Sdn Bhd

With over 30 years of pharmaceutical experience under its belt, Kotra Pharma is well on its way to achieve its mission to be the centre of excellence for the pharmaceutical industry. Having grown from a Malaysian brand to globally recognised in over 30 countries, Kotra Pharma rapid progress did not go unnoticed. Kotra Pharma received one of the highest forms of acknowledgement from the National Pharmaceutical Control Bureau, Ministry of Health Malaysia. , whereby the company was nominated and awarded the inaugural Industry Excellence Award 2012, for its leadership in the field of Good Manufacturing Practice (GMP). Along with this recognition, Kotra Pharma was bestowed from the National Pharmaceutical Company Of The Year for 2011 & 2014 by Frost & Sullivan, a US-based consulting firm, for its leadership in customer value and innovation. These accolades serve to further establish Kotra Pharmau2019s presence within the pharmaceutical industry as well as encourage us as a company to continuously grow and seek better product innovation, manufacturing excellence and geographical expansion to bring accessible healthcare to all. This effort, true to our vision of Humanising Health where we believe everyone deserve a healthier tommorrow, is further supported by Kotra Pharmau2019s commitment to deliver quality medecines to healthcare providers worldwide by applying cutting adge pharmaceutical research and manufacturing technology.u00a0Product & ServicesAt Kotra Pharma, we believe that everyone deserve a healthier tomorrow. Its every individualu2019s right to live a healthy life to the fullest, and thus, we are committed to bring top-notch health products to the world. By humanising healthcare, we see beyond instrument and medicine for the general well-being of everyone. To date, our pharmaceutical (Axcelu00ae and Vaxcelu00ae) and nutraceutical products (Appetonu00ae), have globally benefited patient and communities as we continue to grow, seeking new and and improved ways to constantly fulfill our healthcare needs in an ever changing environment. Committed to our vision, we have invested USD 50 million in the first phase of total USD 150 million state-of-the-art manufacturing and research facilities, which constitute the largest single-investment in the Malaysia pharmaceutical industry to date.u00a0